Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214394 | 0.81 | NOS2 (0.40) | NOS2NOS3ALDH1A1NPC1HPGD | |
| SCHEMBL31214440 | 0.75 | NOS2 (0.35) | NOS2NOS3 | |
| SCHEMBL7850351 | 0.74 | NOS2 (0.50) | NOS2NOS3ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5009720 | 0.72 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL20818537 | 0.72 | NOS2 (0.50) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL18753742 | 0.71 | NOS2 (0.34) | NOS2NOS3ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23857018 | 0.71 | NOS2 (0.44) | NOS2NOS3CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL3899633 | 0.71 | NOS2 (0.44) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL20752742 | 0.71 | NOS2 (0.44) | NOS2NOS3ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL30047488 | 0.71 | NOS2 (0.44) | NOS2NOS3CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | NOS2 3832/4885NOS3 2918/4885ALDH1A1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.